Number of eligible clients: CDEC discussed the uncertainty in the number of sufferers with reasonably extreme to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical gurus consulted by CADTH indicated that some people that are labeled as obtaining gentle or average disorder could possibly have a significant bleeding phen